SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust is capturing significant investor attention as market participants debate whether silver is entering a long-term breakout cycle driven by rising industrial demand and supply chain concerns. Community sentiment is deeply divided, with many traders actively discussing potential short squeezes and hedging strategies while others remain skeptical about the sustainability of current price action amidst broader macroeconomic volatility.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending as investors grapple with a significant disconnect between record-breaking quarterly financial performance and a suppressed stock price. The community is actively debating whether the current price action is driven by institutional manipulation, sector-wide consumer softness, or concerns regarding brand cannibalization and competitive pressure from rivals.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are surging as the company's early-stage research into an mRNA-based Hantavirus vaccine gains renewed attention following a cruise ship outbreak, sparking active discussion among community members debating whether this signals a new pandemic narrative or a short-term trading opportunity. Investors are closely watching for volatility expansion and potential short-squeeze activity as the community remains sharply divided between those betting on long-term vaccine demand and those skeptical of the headlines.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors focus on the impending finalization of its acquisition of Northern Data and anticipation for upcoming earnings, which many in the community believe will validate a fundamental business pivot into AI and cloud infrastructure. While participants are actively debating the impact of a high short interest and the strategic backing of Tether, bullish sentiment remains anchored in the belief that these structural changes will drive a significant valuation re-rate.

Odysight.ai, Inc. engages in the development and manufacture of customized visual solutions for organizations across a variety of industries in the form of micro cameras and supplementary technologies. Its devices can used across the medical, aerospace, industrial, research, and defense industries. The company was founded on March 22, 2013 and is headquartered in Omer, Israel.

Odysight.ai Inc

Odysight.AI Inc

Odysight.AI is generating significant trading activity driven by a new Cooperative Research and Development Agreement with the U.S. Navy for AI-driven visual sensing technology. While some community members are optimistic about the potential for a momentum squeeze and defense sector growth, others are expressing skepticism regarding the company's long-term commercial execution and historical financial performance.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing an aggressive upward trend driven by an intense memory chip supercycle and heavy institutional accumulation as investors scramble to secure HBM and DRAM supply. The community is actively debating the sustainability of this parabolic move, with intense sentiment divided between those expecting a massive short-squeeze to new highs and those warning of a potential blow-off top.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is experiencing significant volatility and community debate as investors weigh strong stablecoin transaction volume against regulatory uncertainty surrounding the CLARITY Act and recent platform security concerns. While traders remain sharply divided on the stock's direction, the conversation is heavily centered on upcoming earnings and how potential legislative clarity will impact its long-term infrastructure role in the crypto ecosystem.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive pre-BLA meeting with the FDA, which confirmed a clear regulatory path toward a late-2026 BLA submission with potential priority review. Community discourse is heavily focused on the company's best-in-class label potential, strong cash position through 2027, and anticipation of upcoming Phase 3 trial data readouts.

Twin Vee PowerCats Co. engages in the design, manufacture, and sale of recreational and commercial power catamaran boats. The firm is focused on designing and developing its products under the ELECTRA Power Sports brand. It operates through the Twin Vee PowerCats and Wizz Banger, Inc. Segments. The Twin Vee PowerCats segment designs, manufactures, and sells recreational and commercial powerboats. The Wizz Banger, Inc. segment refers to a development-stage subsidiary with plans to develop an innovative online marketplace leveraging artificial intelligence (AI) to transform how customers search for and purchase recreational marine assets. The company was founded by Roger Dunshee in 1996 and is headquartered in Fort Pierce, FL.

Twin Vee PowerCats Co

Twin Vee PowerCats is seeing significant retail interest driven by its ultra-low micro-float status and momentum following a reverse stock split. The community is actively discussing the stock's squeeze potential, drawing comparisons to other high-volatility runners and pointing to recent insider buying as a catalyst for a potential parabolic move.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is facing heightened volatility and selling pressure following a revenue guidance miss, as investors weigh strong earnings beats against broader concerns regarding AI disruption in the enterprise SaaS sector. While many community members view the sharp price drop as a disconnect from the company's growth and cash-rich balance sheet, others remain cautious, debating whether established software platforms can effectively pivot or if they are vulnerable to emerging agentic AI competition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Soon-Shiong highlighted that ImmunityBio’s Quilt 3005 immunotherapy is already approved by the Saudi FDA.</li><li>Investors are closely watching the FDA’s ongoing review of ImmunityBio’s resubmitted BLA for Anktiva plus BCG in bladder cancer.</li><li>The filing is backed by Quilt 3.032 data, which showed that 58.2% of patients remained cancer-free after 12 months.</li></ul>Shares of ImmunityBio, Inc. (IBRX) slid over 1% in overnight trading&nbsp;heading into Monday amid lingering review delays from the&nbsp; U.S. Food and Drug Administration (FDA) for the company’s cancer immunotherapy, with founder Patrick Soon-Shiong pointing to Saudi Arabia’s approval and ongoing talks with Greece as silver linings.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> snapped a two-week losing streak last week, surging 20% for its strongest weekly performance since February.&nbsp;<h2 class="st-heading-2">IBRX Greece Meetings Fuel Expansion Buzz</h2>Patrick Soon-Shiong&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2053663752461959277">said on X</a> that the current cancer treatment methods relying on chemotherapy, radiation and checkpoint inhibitors need to evolve toward immunotherapy after citing a New York Times report, which showed that nearly half of advanced lung cancer patients do not receive treatment and about 40% die within three months of diagnosis.&nbsp;“Chemo. Radiation then checkpoints, then even more chemo!!” Soon-Shiong said. “When do we learn that this can change with immunotherapy?” He then pointed to ImmunityBio’s Quilt 3005 program, adding: “Quilt 3005 now approved by Saudi FDA.”&nbsp;The remarks drew investor attention because ImmunityBio’s immunotherapy platform has already gained approval in Saudi Arabia for certain lung cancer patients, while the company continues navigating additional FDA reviews and filings in the U.S.Soon-Shiong separately&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2053227291984191786">posted on X</a> on Sunday about meetings in Greece with Prime Minister Kyriakos Mitsotakis, Health Minister Adonis Georgiadis and Ecumenical Patriarch Bartholomew I. “N.K. cells are God’s gift to humanity and Greece has embraced this for their people,” Soon-Shiong said. “Global expansion continues.”<h2 class="st-heading-2">Anktiva FDA Review In Focus</h2>Another major focus for investors is the FDA’s ongoing review of ImmunityBio’s resubmitted supplemental biologics license application (BLA) for Anktiva, plus standard BCG treatment, in patients with non-muscle-invasive bladder cancer with papillary tumors. The FDA’s standard 60-day filing review window ends anytime now.&nbsp;The filing is backed by long-term data from the Quilt 3.032 study, which ImmunityBio said showed that 58.2% of patients remained cancer-free after 12 months, while more than 80% avoided bladder-removal surgery over three years.<h2 class="st-heading-2">IBRX Investors Watch FDA Shakeup</h2>The FDA backdrop has become even more closely watched after recent turmoil surrounding Commissioner Marty Makary. The Wall Street Journal reported on Friday that U.S. President Donald Trump had signed off on a plan to potentially remove Makary after disputes stemming from vaping approvals, abortion-pill reviews and broader drug policy disagreements.However, Trump later downplayed the report, saying that he knew “nothing about it.” Makary has faced criticism from biotechnology executives, rare-disease advocates and patient groups over FDA review standards and approval decisions involving experimental therapies.The uncertainty matters for biotech companies like ImmunityBio since former Center for Biologics Evaluation and Research (CBER) official Vinay Prasad faced criticism for rejecting or delaying several experimental cancer and rare-disease therapies, while raising approval standards and creating hurdles for accelerated pathways.&nbsp;<h2 class="st-heading-2">ImmunityBio Pushes Overseas Expansion</h2>ImmunityBio has continued to expand globally even as U.S. regulatory scrutiny remains in the spotlight. Earlier this year, the company launched Anktiva in Saudi Arabia for certain patients with bladder and lung cancer through partnerships with Biopharma and Cigalah Healthcare as part of a broader Middle East and North Africa expansion.&nbsp;Anktiva, which was first approved by the U.S. Food and Drug Administration in 2024 for a form of bladder cancer, has since gained approvals in the United Kingdom, European Union and Macau. The European Commission later expanded authorization across 33 countries, while the National Comprehensive Cancer Network (NCCN) added the therapy as an “other recommended” option for papillary bladder cancer.&nbsp;The company also recently faced pressure after the FDA issued a warning letter for promotional claims suggesting broader cancer uses beyond Anktiva’s currently approved bladder cancer indication.<h2 class="st-heading-2">How Do Retail Traders Feel About IBRX?</h2>On Stocktwits, retail sentiment for IBRX was ‘extremely bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_cf2e941a42.webp" alt="ibrx ss.png" width="978" height="143"><figcaption>IBRX sentiment and message volume as of May 10 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/LB19/message/652854070">said</a>, “Each country Patrick locks up the more pressure is on our FDA and Trump. Horrifying look the world is progressing with an American company while America does nothing. This cannot stand. No way.”<stembedurl>https://stocktwits.com/LB19/message/652854070</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/MrMulally/message/652899384">said</a>, “I got a feeling our good Dr. Pat will have a string of PRs coming from various countries.”<stembedurl>https://stocktwits.com/MrMulally/message/652899384</stembedurl>IBRX stock has surged 307% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dxyz-stock-soars-as-spacex-ipo-fever-builds-5b-revenue/cZX9Al7ReWa">DXYZ Stock Soars Overnight As SpaceX IPO Fever Rises: Fund Manager Says Musk's 'Five-Layer Cake' Could Add $5B To Revenue&nbsp;</a>

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Can't Shake FDA Delay Overhang: Founder Touts Saudi And Greece Progress With Anktiva As Bright Spots

Founder Soon-Shiong also posted about meetings in Greece with Prime Minister Kyriakos Mitsotakis and Health Minister Adonis Georgiadis.

Equity

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit...

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC ImmunityBio, Inc. Securities Fraud Class...

IBRX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)

IBRX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX) IBRX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against...

INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with...

<ul class="summary-bullets"><li>IBRX stock extended losses overnight after ImmunityBio reported a Q1 net loss of $632.8 million versus $129.6 million a year ago.</li><li>Founder Patrick Soon-Shiong reignited investor interest after teasing a new Anktiva-based cell therapy trial.</li><li>ImmunityBio said Anktiva demand continued growing across new prescribers and maintenance.</li></ul>Shares of ImmunityBio, Inc. (IBRX) are heading for their best week in over two months as investors shifted focus from the company’s post-earnings selloff toward a newly teased Anktiva combination cell therapy trial.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained 9% so far this week and is on track for its best weekly performance since Feb.27, despite tumbling over 7% on Thursday after the company’s first-quarter (Q1) earnings release.&nbsp;<h2 class="st-heading-2">New Anktiva Combo Trial In Focus</h2>IBRX stock extended its slide in overnight trading on Friday after ImmunityBio reported a Q1 net loss of $632.8 million, compared with $129.6 million a year earlier, while revenue of $44.2 million came in slightly above consensus estimates of $43.9 million.However, founder Patrick Soon-Shiong attempted to add fresh momentum after&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2052616048197661117">posting on X</a> that a Phase 1 trial involving NK-92 cells in refractory lymphoma and multiple myeloma, conducted nearly a decade ago, demonstrated safety and evidence of efficacy, including 2 complete responses. He also said that the company plans to begin a trial combining Anktiva, the company’s flagship immunotherapy, with targeted cell therapy, calling it the “Power of NK and T!”<h2 class="st-heading-2">ImmunityBio Highlights Anktiva Demand</h2>The earnings report still highlighted commercial momentum for Anktiva despite the massive increase in quarterly loss. “We continue to see strong demand for ANKTIVA from both new prescribers and physicians expanding use across multiple eligible patients, including in the maintenance setting,” said Richard Adcock, CEO of ImmunityBio.&nbsp;&nbsp;He also noted that the company expanded market access internationally, with Anktiva now commercially available in Saudi Arabia and additional launches expected later this year.ImmunityBio reported Q1 product revenue growth of 168% from the previous year and ended the quarter with $381 million in cash, cash equivalents and marketable securities.The larger quarterly loss was mainly due to non-cash fair-value changes from warrant liabilities, derivative liabilities and related-party convertible notes, along with higher research, clinical trial and commercialization expenses.<h2 class="st-heading-2">FDA Filing Clock Nears Key Deadline</h2>Another major focus for traders is the FDA’s ongoing review of ImmunityBio’s resubmitted supplemental biologics license application for Anktiva plus standard BCG in patients with a non-muscle invasive bladder cancer with papillary tumors.The FDA’s standard 60-day filing review window is about to expire, after which the agency determines whether the application is complete enough to formally accept for full review and assign a target action date. The filing includes long-term data from the Quilt 3.032 study, which ImmunityBio said showed that 58.2% of patients remained cancer-free after 12 months and that more than 80% avoided bladder-removal surgery over three years.Investor attention is also turning toward next week’s American Urological Association Annual Meeting in Washington, where ImmunityBio plans to present additional Anktiva analyses comparing the therapy against rival bladder cancer treatments, including Johnson &amp; Johnson’s TAR-200 and Nadofaragene Firadenovec. Soon-Shiong is also expected to present new data around IL-15 immune activation and broader immunotherapy approaches.<h2 class="st-heading-2">How Do Retail Traders Feel About IBRX?</h2>On Stocktwits, retail sentiment for IBRX was ‘bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_22976c3755.webp" alt="ibrx ss.png" width="973" height="143"><figcaption>IBRX sentiment and message volume as of May 8 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/2canon/message/652692954">said</a>, “The IBRX community on Stocktwits is more than just investors — we are believers in the vision behind Anktiva and ImmunityBio. Many of us are committed not only financially, but personally, to helping accelerate the life-saving solutions to the world.”<stembedurl>https://stocktwits.com/2canon/message/652692954</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/2canon/message/652692321">said</a>, “Combined with the potential for positive FDA news, this could set up a strong move toward new highs, especially since the company is fundamentally very different from where it was 3 or 6 months ago.”<stembedurl>https://stocktwits.com/2canon/message/652692321</stembedurl>IBRX stock has surged 311% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ino-mrna-nvax-ebs-rally-trump-hantavirus-report-promise/cZX2Jf5ReXB">INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally&nbsp;</a>

Dr. Patrick Soon-Shiong announces newest initiatives for Cancer MoonShot 2020 at Hyatt Regency Boston on October 26, 2016. (Photo by Darren McCollester/Getty Images for NantHealth, Inc.)

IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study

Traders are also watching the FDA review of ImmunityBio’s resubmitted Anktiva plus BCG filing for non-muscle invasive bladder cancer with papillary tumors.

ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum

ImmunityBio shares fall after Q1 losses misses estimates despite strong ANKTIVA sales growth and updated bladder cancer treatment guidelines.read more...

<ul class="summary-bullets"><li>The growth was driven by a 168% increase in sales of its flagship immunotherapy, Anktiva.</li><li>First-quarter net loss came in at $0.62 per share, compared to Street estimates of $0.07 per share.</li><li>ImmunityBio said the wider net loss was mainly due to changes in the value of warrants and derivative liabilities.&nbsp;</li></ul>Retail favorite ImmunityBio (IBRX) was back in the spotlight on Thursday after posting first-quarter earnings, as investors shrugged off a 6% pre-market dip and continued piling into the stock with bullish conviction.<a href="https://stocktwits.com/symbol/IBRX">IBRX shares</a> could snap a six-session winning streak if the stock stays at current levels through Thursday’s close.<h2 class="st-heading-2">Anktiva Drives IBRX’s Q1 Sales Though Loss Widens</h2>ImmunityBio posted a 168% jump in first-quarter (Q1) net sales to $44.2 million, <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-in-spotlight-immunity-bio-guides-for-168-revenue-surge-in-q1-on-anktiva-momentum/cZJWdgmRIrq">in line</a> with its own expectations, but marginally beating Wall Street’s estimates of $43.9 million, according to Fiscal.ai data.The growth was driven by a 168% increase in sales of its flagship immunotherapy, Anktiva. The drug is approved or authorized in 34 countries across five regulatory regions.The results add to FY2025 net product revenue of $113 million, up 700% from 2024, and 15% from the fourth quarter (Q4) of 2025. The company also reported $380.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026, compared to $242.8 million as of Dec. 31, 2025.However, net loss widened significantly to $632.8 million, or $0.62 per share, compared to a loss of $129.6 million, or $0.15 per share. Analysts on average forecast a loss of $0.07 per share. ImmunityBio said the wider net loss was mainly due to changes in the value of warrants and derivative liabilities, as well as a convertible note tied to a related-party transaction.<h2 class="st-heading-2">Retail Dismisses IBRX’s Slide</h2>Despite the pre-market decline, retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while message volumes remained ‘high.’One user sounded positive on the firm’s prospects.<stembedurl>https://stocktwits.com/Larry5500/message/652564259</stembedurl>Another user urged investors to ignore the EPS headline, adding that the “fundamentals are primed” for the FDA deadline.<stembedurl>https://stocktwits.com/smarak1337/message/652562907</stembedurl>The FDA’s 60-day review window for the resubmitted supplemental biologics license application (sBLA) for Anktiva expires on Thursday. The filing includes long-term data showing 58.2% of patients remained cancer-free at one year, while more than 80% avoided bladder removal surgery over three years.The stock has gained around 295% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/peter-brandt-says-silver-could-be-setting-up-for-next-leg-of-rally-hl-paas-ag-stocks-pop-pre-market/cZXbfQVRefU">Peter Brandt Says Silver Could Be Setting Up For Next Leg Of Rally – HL, PAAS, AG Stocks Pop Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Bulls Shrug Off Earnings Loss -- Retail Traders Eye A Crucial FDA Deadline

ImmunityBio posted a first-quarter revenue beat due to surging Anktiva sales.

 IBRX Stock Could Snap 6-Day Winning Streak On Wider Q1 Loss – But Retail Traders Aren't Backing Down

IBRX Lawsuit Alleges Company Allegedly Violated FDA Drug Rules - ImmunityBio Investors Face Losses Following Company Allegedly Violated FDA Drug Rules: SueWallSt

IBRX Lawsuit Alleges Company Allegedly Violated FDA Drug Rules - ImmunityBio Investors Face Losses Following Company Allegedly Violated FDA Drug Rules: SueWallSt IBRX Lawsuit Alleges Company...

ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates

ImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Technology

Energy

Healthcare

Financials

Stocktwits

Stocktwits Polls

Investors are closely watching massive new filings from Vanguard and other top firms that have significantly increased their positions.

Speculation mounts as the company continues to aggressively target international approvals and establish manufacturing hubs outside the US.

Retail sentiment is hyper-focused on upcoming regulatory decisions and potential leadership changes that could fast-track therapy approval.

Traders are betting that heavy institutional buying and limited share availability will force a massive breakout against elevated short interest.

All eyes are on the upcoming presentation at the AUA annual meeting in D.C. as a critical stage for scientific and partnership updates.

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest IBRX News

IBRXImmunityBio Inc